NKGen Biotech to Present at the Alzheimer's Association International Conference 2025

Core Insights - NKGen Biotech, Inc. is set to present its findings on the mechanism of action for troculeucel, a non-genetically modified NK cell therapy for Alzheimer's disease, at the Alzheimer's Association International Conference 2025 [1][2] - The presentation will include Phase I biomarker data that confirms the therapy's enhanced cytotoxicity in Alzheimer's patients [2][3] - Troculeucel is recognized as SNK01 by the World Health Organization, marking a significant milestone in its development for treating neurodegenerative disorders and various cancers [4] Company Overview - NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, focusing on innovative autologous and allogeneic NK cell therapeutics [5] - The company aims to commercialize its therapies, with troculeucel being a key candidate in its pipeline [4][5]